Related Experiment Video
Updated: Aug 2, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Pergolide mesilate may improve fatigue in patients with Parkinson's disease
K Abe1, M Takanashi, T Yanagihara
1Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. abe@neurol.med.osaka-u.ac.jp
Objectives:
Fatigue is a complaint frequently encountered among patients with Parkinson's disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 dopamine receptor agonist) and bromocriptine (a D2 selective dopamine receptor) in patients with PD.
Methods:
We evaluated 41 patients with PD and controls. We assessed the degree of fatigue by using a fatigue scale. The severity of PD was evaluated by the Hoehn and Yahr Scale and the unified Parkinson's disease rating scale (UPDRS).
Results:
After five weeks from prescription, patients taking pergolide mesilate showed significant improvement in the fatigue scale (from 5.1 +/- 0.7 to 4.4 +/- 0.55, p < 0.05, ) but patients taking bromocriptine did not (from 4.8 +/- 0.9 to 4.7 +/- 0.8).
Conclusions:
Our study suggested the possibility of functional correlation between fatigue and D1 receptor in patients with PD.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll

